IGF-I and IGFBP-3 serum levels in patients hospitalized for complications of liver cirrhosis

Ronsoni, Marcelo Fernando; Lazzarotto, César; Fayad, Leonardo; Silva, Mariana Costa; Nogueira, Christiane Lourenço; Bazzo, Maria Luiza; Narciso-Schiavon, Janaína Luz; Dantas-Corrêa, Esther Buzaglo; Schiavon, Leonardon de Lucca

doi:10.1016/s1665-2681(19)31009-9

Cited by 18 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar observations, such as those of IGF1 and IGF2, were done for IGFBP3 levels, which were significantly lower in cirrhotic patients than in controls [ 118 , 121 , 125 , 128 ], in children [ 123 ], as well as in comparison with people with chronic hepatitis C [ 117 , 118 ]. IGFBP3 serum levels, such as IGF1, were related to severity of liver cirrhosis.…”

Section: Evidence From Epidemiologic and Clinicopathological Studisupporting

confidence: 71%

“…Similar changes in IGF1 concentrations, depending on the clinical stage of liver cirrhosis, are also described in children [ 123 ]. IGF1 concentration decreased with the severity of cirrhosis (Child–Pugh score), reaching significantly low values in class C [ 115 , 116 , 124 , 125 , 126 ]. In coinfected HCV/HIV patients, long term reduction of IGF1 levels was also significantly associated with liver stiffness, evaluated in elastography, regardless of HIV status and age [ 127 ].…”

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

“…In coinfected HCV/HIV patients, long term reduction of IGF1 levels was also significantly associated with liver stiffness, evaluated in elastography, regardless of HIV status and age [ 127 ]. The negative correlation between IGF1 and MELD was found [ 125 , 126 , 128 ]. Correlations of serum IGF1 levels with other markers of liver function, including positive correlation with albumin [ 116 , 125 ], and negative with INR, aPTT ratio [ 125 ] and spleen size [ 116 ], were also found.…”

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

“…The negative correlation between IGF1 and MELD was found [ 125 , 126 , 128 ]. Correlations of serum IGF1 levels with other markers of liver function, including positive correlation with albumin [ 116 , 125 ], and negative with INR, aPTT ratio [ 125 ] and spleen size [ 116 ], were also found. IGF1 values of <30 ng/mL were a negative prognostic factor in patients with liver cirrhosis.…”

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

See 3 more Smart Citations

Insulin-Like Growth Factor (IGF) System in Liver Diseases

Adamek

Kasprzak

2018

IJMS

216

149

View full text Add to dashboard Cite

Hepatocyte differentiation, proliferation, and apoptosis are affected by growth factors produced in liver. Insulin-like growth factor 1 and 2 (IGF1 and IGF2) act in response to growth hormone (GH). Other IGF family components include at least six binding proteins (IGFBP1 to 6), manifested by both IGFs develop due to interaction through the type 1 receptor (IGF1R). The data based on animal models and/or in vitro studies suggest the role of IGF system components in cellular aspects of hepatocarcinogenesis (cell cycle progression, uncontrolled proliferation, cell survival, migration, inhibition of apoptosis, protein synthesis and cell growth), and show that systemic IGF1 administration can reduce fibrosis and ameliorate general liver function. In epidemiologic and clinicopathological studies on chronic liver disease (CLD), lowered serum levels, decreased tissue expression of IGF1, elevated production of IGF1R and variable IGF2 expression has been noted, from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage. These changes result in well-known clinical symptoms of IGF1 deficiency. This review summarized the current data of the complex role of IGF system components in the most common CLD (nonalcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma). Better recognition and understanding of this system can contribute to discovery of new and improved versions of current preventive and therapeutic actions in CLD.

show abstract

Section: Evidence From Epidemiologic and Clinicopathological Studisupporting

confidence: 71%

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

See 2 more Smart Citations

Insulin-Like Growth Factor (IGF) System in Liver Diseases

Adamek

Kasprzak

2018

IJMS

216

149

View full text Add to dashboard Cite

show abstract

“…However, the standard system for assessing hepatic reserve in HCC staging systems is the Child-Turcotte-Pugh (CTP) score, which depends on two subjective parameters (encephalopathy and ascites) and three objective parameters (serum albumin, serum bilirubin, and prothrombin time or the international normalized ratio). 107 , 111 , 113 , 116 , 117 , 119 Despite its limitations, the CTP score has remained the standard tool for predicting the degree of underlying CLD in HCC patients before active therapy or trial entry, using CTP class A (CTP-A) as the standard treatable patient population. 124 – 131 Several studies have concluded that patients classified as CTP-B or CTP-C have significantly shorter survival duration than do those classified as CTP-A because of deterioration in their hepatic function.…”

Section: Igf-i As An Assessment Tool For Liver Reserve Capacity In Hcmentioning

confidence: 99%

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

Abdel-Wahab

Shehata

Hassan

et al. 2015

JHC

View full text Add to dashboard Cite

Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child–Turcotte–Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials.

show abstract